CJC and Ipamorelin

As we age, hormones in our body start to decline. We have decrease in growth hormone and insulin-like growth factor 1 (IGF1). IGF1 is what we see raised through taking growth hormone. We also see an increase cellular cortisol (stress hormone). There is a marked decrease in muscle mass and strength. Our insulin sensitivity goes down leading us towards more fat gain. Our cognitive function and memory start to decline. The immune system does not function nearly as well as we age too. Our mitochondria (the powerhouse of each cell in our body) no longer are able to multiply as well as when we were younger.

Growth hormone controls many things in the body such body composition (body fat and lean muscle mass), sleep cycle, bone density, muscle mass, immune function, sexual function, mood, memory, cognition, cardiovascular capacity, endurance, energy, exercise capacity, and glucose utilization. Growth hormone increases levels of insulin-like growth factor 1 (IGF-1). IGF-1 has had multiple studies performed finding things such as high levels of IGF-1 in older men show increased cancer mortality (2). Other studies have found that increased levels of IGF1 lead to decrease risk of mortality (3). When growth hormone is given, it needs to be cycled off and on.  The growth hormone releasing hormone (GHRH) CJC increases growth hormone and IGF-1 levels through a feedback loop in the body (4). Due to being used in a feedback loop, it does not shut down the body’s natural production of growth hormone produced in the pituitary, which happens when just giving growth hormone. The growth hormone-releasing peptide (GRHP) Ipamorelin acts in a similar way on the pituitary as CJC. It increases growth hormone and IGF-1 levels through a feedback loop to the pituitary. Ipamorelin also reduces cell death, decrease reactive oxygen species (ROS), bring down inflammation, and increases how well antioxidants are used in the body. The protective effects of Ipamorelin have been seen in the heart, brain, nerves, stomach, intestines and liver. A reduction in scar tissue post injury has also been seen. Increase ability to create muscle and an inhibition of breakdown of muscle has been found with use of Ipamorelin (1).

Dosing:
Utilizing CJC/Ipamorelin on a daily basis 5 days a week can pulse the growth hormone that is being released from the pituitary. Typically this combination takes roughly 3 months to see peak clinical effectiveness.

What should you expect from CJC/Ipamorelin
The first thing most patients start to notice is an increase in sleep quality. Sleep is one of the most important things in our lives. Dreams can become more vivid. Waking up feeling refreshed also is seen typically in the first two weeks. In the second week, repair in the body starts to become more noticeable. Recovery from exercise is seen during this time. Weeks 3 and 4 have an increase in cognition and feeling like memory becomes easier. Weeks 6 and beyond see a change in body composition with increased lean muscle mass and decreased fat. As lean muscle mass increases, an increase in metabolism occurs. This increased metabolism means more calories being burned off without having to make any dietary changes.

Helps with:
-       Body composition – Body fat decrease, lean muscle mass increase
-       Sleep cycle – slow wave sleep
-       Bone density
-       Muscle mass
-       Immune function
-       Sexual function
-       Mood
-       Memory
-       Cognition
-       Cardiovascular capacity
-       Endurance
-       Energy
-       Exercise capacity
-       Glucose utilization
-       Recovery
-       Wound healing
-       Heart protection
-       Stops telomere shortening
-       Activates stem cells
-       Neuronal repair
-       Works synergistically with hormone replacement therapy
-       COPD
-       CVD
-       Chronic renal failure
-       Chronic respiratory disease

1.     Arvat, E., et al. (1998). Age-related Variations in the Neuroendocrine Control, More than Impaired Receptor Sensitivity, Cause the Reduction in the GH-releasing Activity of GHRPs in Human Aging. Pituitary, 1(1), 51-8. DOI: 10.1023/a:1009970909015
2.     Berlanga-Acosta, J., Abreu-Cruz, A., Herrera, D. G. B., Mendoza-Marí, Y., Rodríguez-Ulloa, A., García-Ojalvo, A., Falcón-Cama, V., Hernández-Bernal, F., Beichen, Q.,  & Guillén-Nieto, G. (2017). Synthetic Growth Hormone-Releasing Peptides (GHRPs): A Historical Appraisal of the Evidences Supporting Their Cytoprotective Effects. Clin Med Insights Cardiol. 11. DOI: 10.1177/1179546817694558
3.     Dioufa, N., et al. (2010). Acceleration of Wound Healing by Growth Hormone-Releasing Hormone and its Agonists. Proc Natl Acad Sci U S A, 107(43), 18611-5. DOI: 10.1073/pnas.1013942107
4.     Friedman, S. D, et al. (2013). Growth Hormone-releasing Hormone Effects on Brain γ-aminobutyric Acid Levels in Mild Cognitive Impairment and Healthy Aging. JAMA Neurol, 70(7), 883-890. DOI: 10.1001/jamaneurol.2013.1425’
5.     Khorram, O., Garthwaite, M., & Golos, T. (2001). The influence of aging and sex hormones on expression of growth hormone-releasing hormone in the human immune system. J Clin Endocrinol Metab, 86(7), 3157-61. DOI: 10.1210/jcem.86.7.7652
6.     Kiaris, H., Chatzistamou, I., Papavassiliou, I. G., Schally, & A. V. (2011). Growth Hormone-releasing Hormone: Not Only a Neurohormone.  Trends Endocrinol Metab, 22(8), 311-7. DOI: 10.1016/j.tem.2011.03.006
7.     Major, J. M., Laughlin, G. A., Kritz-Silverstein, D., Wingard, D. L. & Barrett-Connor, E. (2010). Insulin-Like Growth Factor-I and Cancer Mortality in Older Men. J Clin Endocrinol Metab., 95(3), 1054–1059. DOI: 10.1210/jc.2009-1378
8.     Roubenoff, R., Parise, H., Payette, H. A., Abad, L. A., D'Agostino, R., Jacques, P. F., Wilson, P. W. F., Dinarello, C. A., & Harris, T. B. (2003). Cytokines, Insulin-Like Growth Factor 1, Sarcopenia, and Mortality in Very Old Community-Dwelling Men and Women: The Framingham Heart Study. Am J Med, 115(6), 429-35. DOI: 10.1016/j.amjmed.2003.05.001
9.     Schally, A. V., Steelman, S. L., & Bowers, C. Y. (1965). Effect of Hypothalamic Extracts on Release of Growth Hormone in vitro. Proc Soc Exp Biol Med 119, 208-12. DOI: 10.3181/00379727-119-30138
10. Teichman, S. T., Neale, A., Lawrence, B., Gagnon, C., Castaigne,  J., & Frohman, L. A. (2006). Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-releasing Hormone, in Healthy Adults. J Clin Endocrinol Metab., 91(3), 799-805. DOI: 10.1210/jc.2005-1536.
11. Veldhuis, J. D., Patrie, J. M., Frick, K., Weltman, J. Y., & Weltman, A. L. (2005). Administration of Recombinant Human GHRH-1,44-amide for 3 Months Reduces Abdominal Visceral Fat Mass and Increases Physical Performance Measures in Mostmenopausal Women. Eur J Endocrinol, 153(5), 669-77. DOI: 10.1530/eje.1.02019

Untitled